BioSpace News Archive

Business

ID’ing Exosites to Enable Specificity and Drug Intractable Targets

Exo Therapeutics’ approach is not only different, it has revolutionary potential.

February 13, 2022
·
6 min read
·
Gail Dutton
Policy

U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent

IASO Biotherapeutics and Innovent Biologics, Inc. jointly announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted Orphan Drug Designation to their fully human anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma.

February 13, 2022
·
9 min read
Policy

U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio

Innovent Biologics, Inc. together with IASO Biotherapeutics jointly announced that the U.S. Food and Drug Administration’s Office of Orphan Products Development has formally granted Orphan Drug Designation to their co-developed fully-human B-cell maturation antigen -targeted chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma.

February 13, 2022
·
8 min read
Drug Development

Pluslife Biotech - A Greater Bay Area Company Launches First Handheld Covid-19 Nucleic Acid Test

Recently, Pluslife Biotech, an enterprise based in the Greater Bay Area, launched the first handheld Covid-19 Nucleic Acid Test to help with epidemic prevention and control.

February 13, 2022
·
6 min read
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries

Ascletis Pharma Inc. announces that it has submitted marketing authorization applications for ritonavir in Germany, France, Ireland and United Kingdom through its agent in Europe.

February 13, 2022
·
3 min read